Paul Fonteyne

1,263 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,263
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
10
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • 1.2 Corporate Profile / Ranking
  • 1.2 Corporate Profile / Ranking
  • 3.2 Global Activities and Products / Prescription Medicines
  • Paul Fonteyne

    1. 1. Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical Industry Leader in Fairfield County
    2. 2. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 2 Ridgefield, Connecticut
    3. 3. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 3 Background • Founded in 1885 in Ingelheim, Germany • World’s largest family-owned pharmaceutical company • Operates worldwide - 156 affiliated companies in over 60 countries • Focus: Human Pharmaceuticals (95%) and Animal Health • Products in a variety of therapeutic areas - Cardiovascular, Respiratory, CNS, Virology, Oncology, Immunology, Urology, Rheumatology, GI/Metabolic • Research focused - Medicines for those diseases where genuine therapeutic innovation can be demonstrated.
    4. 4. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 4 Worldwide - 2004 •Total Net Sales $ 10.2 Billion -Human Pharma 96% -Animal Health 4% •Total Employees nearly 36,000 •R&D+C Expenditures $ 1.23 Billion
    5. 5. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 5 Top 20 Corporations 2004 Global Pharma Market 40 35 30 25 20 15 10 5 Source: IMS Health, IMS Health / MAT Q4 2004 in EUR billion Pfizer G laxosm ithkline Sanofi-Aventis Johnson & Johnson M erck & Co Novartis Astrazeneca Roche Bristol-M yers SQ B. W yeth Abbott Lilly Am gen Takeda Boehringer Ingelheim Schering Plough Bayer Yam anouchi-Fujisawa Eisai Schering AG 37.8 23.4 19.5 18.3 17.8 16.3 15.9 12.4 11.2 10.4 10.3 9.3 7.9 6.8 6.1 4.9 4.5 3.9 3.7 3.4
    6. 6. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 6 Top 20 Corporations ranked by Growth 30 25 20 15 10 5 -5 -10 -15 -20 Boehringer Ingelheim Growth Rate above Top 20 Corporations (+8.2%) MAT to Q4 2004 in Constant Euro in % Am gen Boehringer Ingelheim Roche Abbott Astrazeneca Sanofi-Aventis W yeth Esai Johnson & Johnson Novartis Schering AG Lilly Takeda Pfizer M erck & Co G laxosm ithkline Yam anouchi- FujisawaBayer Bristol-M yers SQ B. Schering Plough 25.5 14.3 10.2 9.4 9.2 9.0 9.0 8.4 8.0 7.3 6.4 6.1 5.8 4.7 3.5 1.8 -1.2 -3.9 -13.2 1.3 Source: IMS Health, IMS Health / MAT Q4 2004
    7. 7. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 7 Prescription Medicines Our Six Highlights flomax® mobic® micardis® viramune® spiriva® mirapex®
    8. 8. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 8 Ridgefield Campus Projects • Lead Discovery Technologies Building dedicated in 2001 • Kilo Lab • Completed in 2005, produces drug substances up to 5 kg quantities for research purposes. • On-site Child Care Center; September 2006 • 19,000 sq ft stand alone building with a capacity for 256 infants, toddlers and preschoolers. • Physical Sciences building; March 2007 • 86,000 sq ft building to accommodate relocation of our cardiovascular diseases research program from Germany. • 3 floors, 119 work stations for scientists and
    9. 9. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 9 BI Cares Foundation The Foundation’s mission is to improve lives through innovative philanthropic contributions and donations of healthcare products and resources. • BI Cares Foundation Patient Assistance Plan (170,000 patients expected to be enrolled in 2005) • Hurricane Rita and Katrina assistance • Product Donation Program ($160M in product donation anticipated in 2005) • Cash contributions in 2004 - $1.9M
    10. 10. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 10 Community Involvement - CT • Lung Health Screening Program • United Way of Northern Fairfield County • Regional Hospice of Western Connecticut • American Red Cross • Connecticut PBS – Family Science Expo • Abilities Beyond Disabilities (DATAHR) • Connecticut United for Research Excellence • Ives Center for the Arts • Girl Scout Council of SW Connecticut • Regional YMCA Center for Arts & Humanities • Special Olympics – Connecticut • Western Connecticut State University
    11. 11. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 11 Pharmaceutical Industry Challenges - Government • Prescription drug importation • AKA price controls • Promotion restrictions • Lower market penetration of new products • Increased costs of doing business • Energy, taxes, fees, liability
    12. 12. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 12 • Continued innovation • Continued ability to fund R&D • Cost of and time to develop new products • Attracting talented, highly educated workforce • Continue to effectively and efficiently serve a diverse and changing marketplace • Physicians, patients, institutions, payors Pharmaceutical Industry Challenges - Industry
    13. 13. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 13 Summary • BI is a growing, innovative pharmaceutical company and employer in Fairfield County • BI is committed to delivering value to patients and to the healthcare community • Challenges to the healthcare marketplace and pharmaceutical industry are significant
    14. 14. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 14 Web information • http://www.boehringer-ingelheim.com Worldwide web • http://us.boehringer-ingelheim.com US company web • https://www.pparx.org/Intro.php Partnership for Prescription Assistance • http://us.boehringer-ingelheim.com/about/philanthropy/Patie BI Cares Foundation Patient Assistance web
    15. 15. Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical Industry Leader in Fairfield County

    ×